Exploiting temporal aspects of cancer immunotherapy

被引:6
|
作者
Zemek, Rachael M. [1 ,2 ]
Anagnostou, Valsamo [3 ]
Pires da Silva, Ines [4 ,5 ,6 ,7 ]
Long, Georgina V. [4 ,5 ,6 ,8 ]
Lesterhuis, Willem Joost [1 ]
机构
[1] Univ Western Australia, Telethon Kids Inst, Perth, WA, Australia
[2] Fred Hutchinson Canc Ctr, Vaccine & Infect Dis Div, Seattle, WA USA
[3] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
[5] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia
[6] Univ Sydney, Charles Perkins Ctr, Sydney, NSW, Australia
[7] Blacktown Hosp, Crown Princess Mary Canc Ctr, Sydney, NSW, Australia
[8] Royal North Shore & Mater Hosp, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
IMMUNE CHECKPOINT BLOCKADE; STAGE-III MELANOMA; CELL LUNG-CANCER; PD-1; BLOCKADE; T-CELLS; TUMOR MICROENVIRONMENT; LYMPHOID STRUCTURES; BRAF INHIBITION; B-CELLS; ANTITUMOR IMMUNITY;
D O I
10.1038/s41568-024-00699-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Many mechanisms underlying an effective immunotherapy-induced antitumour response are transient and critically time dependent. This is equally true for several immunological events in the tumour microenvironment induced by other cancer treatments. Immune checkpoint therapy (ICT) has proven to be very effective in the treatment of some cancers, but unfortunately, with many cancer types, most patients do not experience a benefit. To improve outcomes, a multitude of clinical trials are testing combinations of ICT with various other treatment modalities. Ideally, those combination treatments should take time-dependent immunological events into account. Recent studies have started to map the dynamic cellular and molecular changes that occur during treatment with ICT, in the tumour and systemically. Here, we overlay the dynamic ICT response with the therapeutic response following surgery, radiotherapy, chemotherapy and targeted therapies. We propose that by combining treatments in a time-conscious manner, we may optimally exploit the interactions between the individual therapies. The tumour immune microenvironment greatly affects responses to immune checkpoint therapies. In this Perspective, Zemek et al. explore the dynamic changes in response to both immunotherapy and conventional treatment and advocate for strategic combination therapies over time to enhance antitumour immune responses.
引用
收藏
页码:480 / 497
页数:18
相关论文
共 50 条
  • [1] Exploiting bacteria for cancer immunotherapy
    Kwon, Seong-Young
    Ngo, Hien Thi-Thu
    Son, Jinbae
    Hong, Yeongjin
    Min, Jung-Joon
    NATURE REVIEWS CLINICAL ONCOLOGY, 2024, 21 (08) : 569 - 589
  • [2] Cancer immunotherapy: exploiting neoepitopes
    Platten, Michael
    Offringa, Rienk
    CELL RESEARCH, 2015, 25 (08) : 887 - 888
  • [3] Cancer immunotherapy: exploiting neoepitopes
    Michael Platten
    Rienk Offringa
    Cell Research, 2015, 25 : 887 - 888
  • [4] Exploiting innate immunity for cancer immunotherapy
    Yi, Ming
    Li, Tianye
    Niu, Mengke
    Mei, Qi
    Zhao, Bin
    Chu, Qian
    Dai, Zhijun
    Wu, Kongming
    MOLECULAR CANCER, 2023, 22 (01)
  • [5] Exploiting innate immunity for cancer immunotherapy
    Ming Yi
    Tianye Li
    Mengke Niu
    Qi Mei
    Bin Zhao
    Qian Chu
    Zhijun Dai
    Kongming Wu
    Molecular Cancer, 22
  • [6] Aspects of cancer immunotherapy
    Mckenzie, IF
    Apostolopoulos, V
    Plebanski, M
    Pietersz, GA
    Loveland, BE
    IMMUNOLOGY AND CELL BIOLOGY, 2003, 81 (01): : 79 - 85
  • [7] The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy
    Yau, Helen Loo
    Ettayebi, Ilias
    De Carvalho, Daniel D.
    TRENDS IN CELL BIOLOGY, 2019, 29 (01) : 31 - 43
  • [8] CURRENT ASPECTS OF IMMUNOTHERAPY IN CANCER
    BETZLER, M
    DIEHL, V
    MATHE, G
    HAVEMANN, K
    WYBRAN, H
    WANEBO, HJ
    LANGENBECKS ARCHIV FUR CHIRURGIE, 1981, 354 (01): : 1 - 17
  • [9] Temporal aspects of cancer
    Carricaburu, D
    REVUE FRANCAISE DE SOCIOLOGIE, 2000, 41 (04): : 806 - 808
  • [10] Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy
    Tahtinen, Siri
    Feola, Sara
    Capasso, Cristian
    Laustio, Netta
    Groeneveldt, Christianne
    Ylosmaki, Erkko O.
    Ylosmaki, Leena
    Martins, Beatriz
    Fusciello, Manlio
    Medeot, Marta
    Tagliamonte, Maria
    Chiaro, Jacopo
    Hamdan, Firas
    Peltonen, Karita
    Ranki, Tuuli
    Buonaguro, Luigi
    Cerullo, Vincenzo
    CANCER RESEARCH, 2020, 80 (12) : 2575 - 2585